Genetic testing is increasingly integrated as a prognostic marker in long-QT syndrome, and beta-blocker efficacy appears to be substance-specific, emphasizing the need for individualized management in specialized clinics.
This review outlines our current understanding and approach to the clinical diagnosis and management of LQT as well as recent insights into genotype-phenotype correlations. Genetic testing has evolved beyond a pure diagnostic tool and is in addition increasingly integrated as complementary prognostic marker. With regard to the management of LQT, there is now evidence that the protective effect of beta-blockers is rather substance-specific than a class effect. Novel approaches - in conjunction with standard beta-blockers - are emerging including gene-specific treatment for certain subtypes of LQT. A specialized inherited arrhythmia clinic is the preferred resource for the complex risk stratification and individualized management of individuals with LQT.
No takes yet. Share an insight, caveat, or question.
Christian Steinberg (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: